Atropine has been the apparent hero of myopia management since the 2006 ATOM1 study, and since then, low concentration 0.01% atropine has become the new hero and then fallen out of favour. This article describes how lower concentrations work to balance efficacy and side effects, which should we select now, and what newer research on formulations and combinations can tell us.
Binocular vision is a much neglected (and even maligned?) domain of eye care where I’ve had numerous colleagues say their professional excitement and learning opportunities have been reinvigorated through seeing the clinical imperative and application in practice. Not only does binocular vision assessment add so much more to your clinical picture, and make optometric life more interesting, it could be the secret sauce that helps us bridge the gap towards 100% efficacy.
Myopia control is vital for children with fast myopia progression. What are the key risk factors for faster myopia progression? What clinical findings indicate a more proactive myopia management strategy may be required? This case describes risk factors and evidence-based treatment options for fast myopia progressors.
When setting myopia control expectations both at outset and follow up, it is important to compare the child’s observed myopia progression to ‘average’, and to then judge the expected outcomes of treatment. Bringing their lifestyle, motivations and abilities into consideration is also important. Here we explore how to use resources in practice to set expectations and gauge success along the way.